Table 5.

Multivariate Cox regression analysis A) for HER2, B) for TOP2A and C) for both HER2 and TOP2A, adjusted for significant clinicopathological parameters in terms of DFS and OS

		Disease-free survival			Overall survival
		HR	95% C.I.	Wald's p	HR	95% C.I.	Wald's p
A)	Group
	E-CMF vs E-T-CMF	1.07	0.72-1.59	0.75	1.58	0.96-2.60	0.071
	Tumor size
	2-5 cm vs < 2 cm	1.62	0.99-2.67	0.056
	> 5 cm vs < 2 cm	1.73	0.92-3.22	0.087
	Adjuvant HT
	Yes vs No	0.50	0.27-0.94	0.031
	Nodal involvement
	≥ 4 vs 0-3	2.16	1.19-3.93	0.011	1.83	0.92-3.61	0.082
	Hormone receptor status
	Positive vs Negative				0.54	0.30-0.94	0.030
	Ki67
	High vs Low	1.69	0.91-3.15	0.096	3.54	1.27-9.84	0.015
	HER2 (mRNA)
	High vs Low	1.68	1.10-2.58	0.016	1.77	1.04-3.02	0.035
B)	Group
	E-CMF vs E-T-CMF	1.20	0.79-1.82	0.40	1.58	0.96-2.60	0.071
	Nodal involvement
	≥ 4 vs 0-3	3.03	1.56-5.85	0.001	2.21	1.11-4.38	0.024
	Hormone receptor status
	Positive vs Negative	0.49	0.31-0.78	0.003	0.42	0.24-0.71	0.001
	Ki67
	High vs Low	2.04	1.05-3.97	0.035	3.50	1.25-9.76	0.017
	TOP2A (CISH)
	Amplified vs Non-amplified	0.29	0.09-0.93	0.038
	TOP2A (mRNA)
	High vs Low				2.08	1.24-3.47	0.005
C)	Group
	E-CMF vs E-T-CMF	1.17	0.74-1.84	0.51	1.60	0.97-2.64	0.065
	Nodal involvement
	≥ 4 vs 0-3	2.82	1.39-5.71	0.004	2.09	1.05-4.16	0.036
	Hormone receptor status
	Positive vs Negative	0.56	0.33-0.96	0.035	0.49	0.28-0.86	0.014
	Ki67
	High vs Low	2.24	1.01-4.98	0.048	3.18	1.13-8.92	0.028
	HER2 (mRNA)
	High vs Low	1.80	1.10-2.93	0.019	1.73	1.02-2.93	0.040
	TOP2A (CISH)
	Amplified vs Non-amplified	0.36	0.11-1.17	0.091
	TOP2A (mRNA)
	High vs Low	1.52	0.97-2.41	0.070	2.06	1.23-3.46	0.006

HT, hormonotherapy